CANDACE WOOTEN-REED: Open Payments
NPI 1750529764 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,084 in 60 payments from 23 companies in 2025. Trend: 2023 $1,942 · 2024 $1,770 · 2025 $1,084
Food & beverage: $1,084
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $150 |
| ABBVIE INC. | 11 | $138 |
| ViiV Healthcare Company | 5 | $105 |
| Lilly USA, LLC | 6 | $90 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| Amgen Inc. | 3 | $47 |
| Gilead Sciences, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
Products named: APRETUDE, LINZESS, Wegovy, MOUNJARO, REZDIFFRA, ZENPEP, JARDIANCE, VOQUEZNA.
Industry payments across GA — which companies pay providers there.
